IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trialGuruFocus · 5 hr ago
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCERGuruFocus · 5 hr ago
Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026GuruFocus · 8 hr ago
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026GuruFocus · 13 hr ago
Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study UpdateMarketBeat · 23 hr ago
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal CancerGuruFocus · 1 day agoProvident Financial Services, Inc. functions as the parent company for Provident Bank, delivering a broad spectrum of financial products and services to individuals, families, and businesses across the United States. Its deposit offerings encompass various account types, including savings, standard and interest-bearing checking accounts, money market accounts, certificates of deposit, and IRA products. The company's extensive loan portfolio features commercial real estate loans, which are collateralized by properties such as multi-family apartment complexes, office buildings, retail spaces, and industrial sites.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 29, 2026 | $0.57 | $0.60 | Beat |
| Apr 29, 2026 | $0.55 | $0.61 | Beat |
| Jan 27, 2026 | $0.56 | $0.64 | Beat |
| Oct 29, 2025 | $0.54 | $0.55 | Beat |
| Jul 24, 2025 | $0.50 | $0.55 | Beat |
| Apr 24, 2025 | $0.47 | $0.50 | Beat |